ArticleInternational ophthalmology2024
The role of serum biomarkers in determining systemic inflammation and cardiovascular risk in pseudoexfoliation syndrome.
Article in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06946030 (The Relationship Between Ocular Pseudoexfoliation Syndrome and Carpal Tunnel Syndrome), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Relationship Between Ocular Pseudoexfoliation Syndrome and Carpal Tunnel Syndrome
Who cites it
4 citing papers in PubMed.
- Triad of homocysteine, ROCK2 and vimentin as a convergent biomarker signature in pseudoexfoliation.Journal of translational medicine · 2025Article
- The relationship between pan-immune inflammation value and different stages of diabetic retinopathy in patients with type 2 diabetes mellitus: a prospective cross-sectional study.BMC endocrine disorders · 2025Article
- miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease-A New Diagnostic Path?Biomedicines · 2025Article
- Systemic Immune-Inflammation Index and Unconjugated Bilirubin Levels Are Associated with Pseudoexfoliation Syndrome.Journal of ophthalmic & vision research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the role of hematological and atherogenic biomarkers in evaluating systemic inflammation and cardiovascular risk in patients with pseudoexfoliation syndrome.
methodsThis retrospective study included 200 patients, 90 with pseudoexfoliation (PEX) syndrome (Group 1) and 110 healthy controls (Group 2). Twelve-hour fasting blood samples were collected to measure complete blood count, neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII) (neutrophil x platelet/lymphocyte), systemic inflammatory response index (SIRI) (neutrophil x monocyte/lymphocyte), pan-immune inflammation value (PIV) (neutrophil x platelet x monocyte/lymphocyte), C-reactive protein (CRP), uric acid, glucose, triglycerides (TG), total cholesterol, HDL, LDL, non-HDL, and triglyceride-glucose (TyG) index (Ln (TG [mg/dL] × glucose [mg/dL]/2)). The groups were compared based on these measurements.
resultsThe two groups were similar in terms of age and gender (p > 0.05). No statistically significant differences were observed between the groups for PLR, SII, CRP, glucose, total cholesterol, HDL, LDL, and non-HDL (all p > 0.05). However, systemic inflammation markers-NLR, MLR, SIRI, PIV, and uric acid were significantly higher in Group 1 compared to Group 2 (all p < 0.05). Among the atherogenic biomarkers used to assess cardiovascular risk, triglycerides and the TyG index were significantly higher in Group 1 (p < 0.05, p < 0.001).
conclusionPseudoexfoliation syndrome is characterized by the accumulation of fibrogranular material primarily on the anterior lens capsule and pupillary border. PEX deposits are not limited to ocular structures but are also found in the heart, liver, and various vascular structures. It has been suggested that PEX is an independent risk factor for cardiovascular diseases and that systemic inflammation plays a role in the disease's pathogenesis. The significant biomarkers identified in this study may provide guidance in monitoring the disease.
Indexed as
Identifiers
39699776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.